• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Seres Therapeutics Inc (NQ: MCRB )

    0.8119 +0.0045 (+0.56%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Seres Therapeutics Inc

    < Previous 1 2 3 4 Next >
    MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Highlight VOWST™ Data at IDWeek
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Named to TIME100 Most Influential Companies List
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.